Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma
- PMID: 32140709
- PMCID: PMC7953494
- DOI: 10.1042/BSR20193353
Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma
Abstract
Cholangiocarcinoma (CCA) is a fatal malignant tumor of biliary epithelial cells involving intra- or extra-hepatic bile ducts. The prognosis of CCA is generally poor due to its diagnosis at the late stages. The currently employed chemotherapeutic agents do not increase the survival rate in patients with unresectable CCA. Accordingly, there is a need to identify new therapeutic agents for the effective management of intra- and extra-hepatic CCA. Clinical as well as preclinical studies have suggested the key role of the activation of Wnt/β-catenin signaling pathway in the induction and progression of CCA. There is an up-regulation of different Wnt ligands including Wnt2, Wnt3, Wnt5, Wnt7 and Wnt10 along with redistribution of β-catenin (more expression in the nucleus and lesser on the cell surface due to nuclear translocation of β-catenin) in different types of malignant biliary tumors. Apart from the role of this pathway in the induction and progression of CCA, this pathway is also involved in inducing multidrug resistance by inducing the expression of P-glycoprotein efflux pump on the cancer cells. These deleterious effects of Wnt/β-catenin signaling are mediated in association with other signaling pathways involving microRNAs (miRNAs), PI3K/AKT/PTEN/GSK-3β, retinoic acid receptors (RARs), dickkopf-1 (DKK1), protein kinase A regulatory subunit 1 α (PRKAR1A/PKAI), (SLAP), liver kinase B1 (LKB1) and CXCR4. The selective inhibitors of Wnt/β-catenin signaling may be potentially employed to overcome multidrug-resistant, fatal CCA. The present review discusses the role of Wnt/β-catenin along with its relation with other signaling pathways in the induction and progression of CCA.
Keywords: Wnt; cholangiocarcinoma; macrophages; miRNA; β-catenin.
© 2020 The Author(s).
Conflict of interest statement
The authors declare that there are no competing interests associated with the manuscript.
Figures
Similar articles
-
Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity.Cells. 2023 Apr 12;12(8):1141. doi: 10.3390/cells12081141. Cells. 2023. PMID: 37190050 Free PMC article. Review.
-
Guanine nucleotide exchange factor T exerts the cancer-promoting function in cholangiocarcinoma by enhancing the Wnt-GSK-3β-β-catenin cascade via regulation of Rac1/Cdc42.Toxicol Appl Pharmacol. 2023 May 15;467:116492. doi: 10.1016/j.taap.2023.116492. Epub 2023 Mar 26. Toxicol Appl Pharmacol. 2023. PMID: 36977438
-
Opisthorchis viverrini infection activates the PI3K/ AKT/PTEN and Wnt/β-catenin signaling pathways in a Cholangiocarcinogenesis model.Asian Pac J Cancer Prev. 2014;15(23):10463-8. doi: 10.7314/apjcp.2014.15.23.10463. Asian Pac J Cancer Prev. 2014. PMID: 25556493
-
Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.Tumour Biol. 2013 Dec;34(6):3637-48. doi: 10.1007/s13277-013-0945-2. Epub 2013 Jul 6. Tumour Biol. 2013. PMID: 23832540
-
WNT/β-catenin signaling in the development of liver cancers.Biomed Pharmacother. 2020 Dec;132:110851. doi: 10.1016/j.biopha.2020.110851. Epub 2020 Oct 17. Biomed Pharmacother. 2020. PMID: 33080466 Review.
Cited by
-
WSB1 Involvement in Prostate Cancer Progression.Genes (Basel). 2023 Jul 29;14(8):1558. doi: 10.3390/genes14081558. Genes (Basel). 2023. PMID: 37628609 Free PMC article.
-
Sevoflurane inhibits cholangiocarcinoma via Wnt/β-catenin signaling pathway.BMC Gastroenterol. 2023 Aug 11;23(1):279. doi: 10.1186/s12876-023-02911-3. BMC Gastroenterol. 2023. PMID: 37568083 Free PMC article.
-
Infectious Agents Induce Wnt/β-Catenin Pathway Deregulation in Primary Liver Cancers.Microorganisms. 2023 Jun 22;11(7):1632. doi: 10.3390/microorganisms11071632. Microorganisms. 2023. PMID: 37512809 Free PMC article. Review.
-
Calcyclin-binding protein contributes to cholangiocarcinoma progression by inhibiting ubiquitination of MCM2.Oncol Res. 2023 May 24;31(3):317-331. doi: 10.32604/or.2023.028418. eCollection 2023. Oncol Res. 2023. PMID: 37305391 Free PMC article.
-
Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity.Cells. 2023 Apr 12;12(8):1141. doi: 10.3390/cells12081141. Cells. 2023. PMID: 37190050 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
